[{"id":"04bf9f33-c206-4fb2-ae58-5f4002359115","acronym":"","url":"https://clinicaltrials.gov/study/NCT03267654","created_at":"2021-01-18T16:08:27.490Z","updated_at":"2024-07-02T16:36:42.458Z","phase":"Phase 2","brief_title":"Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance","source_id_and_acronym":"NCT03267654","lead_sponsor":"Qilu Pharmaceutical Co., Ltd.","biomarkers":" EGFR • BCL2","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • BCL2L11 deletion","tags":["EGFR • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • BCL2L11 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gefitinib • AiTan (rivoceranib)"],"overall_status":"Unknown status","enrollment":" Enrollment 100","initiation":"Initiation: 10/12/2017","start_date":" 10/12/2017","primary_txt":" Primary completion: 10/20/2020","primary_completion_date":" 10/20/2020","study_txt":" Completion: 12/30/2021","study_completion_date":" 12/30/2021","last_update_posted":"2020-08-03"}]